AstraZeneca PLC (AZN) Stock AnalysisAZNAstraZeneca PLC

AstraZeneca PLC is a United Kingdom-based science-led biopharmaceutical company. The Company focuses on the discovery, development, and commercialization of prescription medicines. The Company operates across therapy areas, including Oncology; Cardiovascular, Renal and Metabolism (CVRM); Respiratory and Immunology (R&I); Vaccines and Immune Therapies (V&I), and Rare Disease. In the Oncology area, its key products include Tagrisso, Imfinzi, Calquence, Lynparza, and Enhertu. The key products of CVRM area include Farxiga/Forxiga, Brilinta/Brilique, Crestor, and Lokelma. In the R&I area, the key products are Symbicort, Fasenra, Breztri/Trixeo, and Tezspire. In the V&I Therapies area, the products are Beyfortus and FluMist. The products in the Rare Disease area are Ultomiris, Soliris, Strensiq, and Koselugo. It has about 191 projects in its development pipeline, including 19 new molecular entities (NMEs) in the late-stage pipeline. The Company distributes its products in over 125 countries. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

AstraZeneca PLC is a good buy right now, with a current price of $159.20 and a forward P/E ratio of 14.62, indicating it is undervalued compared to its earnings potential. The company has shown a significant year-to-date change of +73.86%, reflecting strong market performance. The main risk is the RSI of 43.35, suggesting potential weakness in momentum, but the overall growth outlook remains positive due to strong revenue growth and analyst support.

5 analysts cover AZN: 4 rate it Buy, 1 Hold and 0 Sell. The average price target is 213.64.